What Did We Really Learn From Phase I Trial For Epizyme's New Drug?

On November 14, 2013, Epizyme presented results of the Phase I trial data for EPZ-5676, a small molecule inhibitor of DOT1L.

http://seekingalpha.com/article/1853961-what-did-we-really-learn-from-phase-i-trial-for-epizymes-new-drug?source=feed